Conditioning of naive CD4+ T cells for enhanced peripheral Foxp3 induction by nonspecific bystander inflammation

Nature Immunology

Volumn 17, Issue 3, 2016, Pages 297-303

  Thompson, Lucas J ^a   Lai, Jen Feng ^a   Valladao, Andrea C ^a,b   Thelen, Tennille D ^a,b   Urry, Zoe L ^c   Ziegler, Steven F ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; AUTOANTIGEN; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; INTERFERON INDUCING AGENT; POLYINOSINIC POLYCYTIDYLIC ACID; THYMIC STROMAL LYMPHOPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; ASTHMA; AUTOIMMUNITY; BYSTANDER EFFECT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HELPER CELL; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOREGULATION; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRE T LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT INFLAMMATION; VIRUS INFECTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DIABETES MELLITUS; DISEASE MODEL; DNA METHYLATION; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PROMOTER REGION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ASTHMA; AUTOANTIGENS; AUTOIMMUNITY; BYSTANDER EFFECT; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DNA METHYLATION; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; INFLAMMATION; INTERFERON INDUCERS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PERIPHERAL TOLERANCE; POLY I-C; PROMOTER REGIONS, GENETIC; SELF TOLERANCE;

EID: 84954543544     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3329     Document Type: Article

References (51)

1. Yoshimura A., Naka T., & Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7, 454-465 (2007
2. Schmitz M.L., Weber A., Roxlau T., Gaestel M., & Kracht M. Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines. Biochim. Biophys. Acta 1813, 2165-2175 (2011
3. Scott-Browne J.P., et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J. Exp. Med. 204, 2159-2169 (2007
4. Haribhai D., et al. A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity 35, 109-122 (2011
5. Bilate A.M., & Lafaille J.J. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu. Rev. Immunol. 30, 733-758 (2012
6. Janeway C.A. Jr., & Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002
7. Van Duin D., Medzhitov R., & Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol. 27, 49-55 (2006
8. Thompson L.J., Valladao A.C., & Ziegler S.F. Cutting edge: De novo induction of functional Foxp3+ regulatory CD4 T cells in response to tissue-restricted self antigen. J. Immunol. 186, 4551-4555 (2011
9. Srivastava S., Koch M.A., Pepper M., & Campbell D.J. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J. Exp. Med. 211, 961-974 (2014
10. Coffman R.L., Sher A., & Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492-503 (2010
11. Boyman O. Bystander activation of CD4+ T cells. Eur. J. Immunol. 40, 936-939 (2010
12. Christen U., & von Herrath M.G. Do viral infections protect from or enhance type 1 diabetes and how can we tell the difference?. Cell. Mol. Immunol. 8, 193-198 (2011
13. Mills K.H. TLR-dependent T cell activation in autoimmunity. Nat. Rev. Immunol. 11, 807-822 (2011
14. Bach J.F. Infections and autoimmune diseases. J. Autoimmun. 25 (suppl.) 74-80 (2005
15. Headley M.B., et al. TSLP conditions the lung immune environment for the generation of pathogenic innate and antigen-specific adaptive immune responses. J. Immunol. 182, 1641-1647 (2009
16. Durrant D.M., & Metzger D.W. Emerging roles of T helper subsets in the pathogenesis of asthma. Immunol. Invest. 39, 526-549 (2010
17. Saff R.R., Spanjaard E.S., Hohlbaum A.M., & Marshak-Rothstein A. Activation-induced cell death limits effector function of CD4 tumor-specific T cells. J. Immunol. 172, 6598-6606 (2004
18. Takahashi R., et al. SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-γ and IL-17A production. J. Exp. Med. 208, 2055-2067 (2011
19. Lu L.F., et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30, 80-91 (2009
20. Haxhinasto S., Mathis D., & Benoist C. The AKT-mTOR axis regulates De novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205, 565-574 (2008
21. Delgoffe G.M., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832-844 (2009
22. Yamane H., & Paul W.E. Early signaling events that underlie fate decisions of naive CD4+ T cells toward distinct T-helper cell subsets. Immunol. Rev. 252, 12-23 (2013
23. Wei J., et al. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. USA 104, 18169-18174 (2007
24. Bettelli E., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006
25. Wang Y., et al. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 11, 631-642 (2012
26. Barchet W., et al. Virus-induced interferon-α production by a dendritic cell subset in the absence of feedback signaling in vivo. J. Exp. Med. 195, 507-516 (2002
27. Matsumoto M., & Seya T. TLR3: interferon induction by double-stranded RNA including poly(I: C). Adv. Drug Deliv. Rev. 60, 805-812 (2008
28. Liu Y., et al. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat. Med. 20, 272-282 (2014
29. Dumont F.J., & Coker L.Z. Interferon-α/β enhances the expression of Ly-6 antigens on T cells in vivo and in vitro. Eur. J. Immunol. 16, 735-740 (1986
30. Taniguchi T., & Takaoka A. A weak signal for strong responses: interferon-α/β revisited. Nat. Rev. Mol. Cell Biol. 2, 378-386 (2001
31. Knutson K.L., & Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54, 721-728 (2005
32. Zhou G., Drake C.G., & Levitsky H.I. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107, 628-636 (2006
33. Zhou G., & Levitsky H.I. Natural regulatory T cells and De novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 178, 2155-2162 (2007
34. Zhou L., et al. TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function. Nature 453, 236-240 (2008
35. Miyao T., et al. Plasticity of Foxp3+ T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 36, 262-275 (2012
36. Longhi M.P., et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206, 1589-1602 (2009
37. González-Navajas J.M., Lee J., David M., & Raz E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12, 125-135 (2012
38. Teijaro J.R., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207-211 (2013
39. Wilson E.B., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202-207 (2013
40. Stelekati E., et al. Bystander chronic infection negatively impacts development of CD8+ T cell memory. Immunity 40, 801-813 (2014
41. Osokine I., et al. Type I interferon suppresses De novo virus-specific CD4 Th1 immunity during an established persistent viral infection. Proc. Natl. Acad. Sci. USA 111, 7409-7414 (2014
42. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347, 911-920 (2002
43. Dunn G.P., Koebel C.M., & Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836-848 (2006
44. Grivennikov S.I., Greten F.R., & Karin M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010
45. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 30, 677-706 (2012
46. Conroy H., Marshall N.A., & Mills K.H. TLR ligand suppression or enhancement of Treg cells?. A double-edged sword in immunity to tumours. Oncogene 27, 168-180 (2008
47. Virgin H.W., Wherry E.J., & Ahmed R. Redefining chronic viral infection. Cell 138, 30-50 (2009
48. Koch M.A., et al. T-bet+ Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor-β2. Immunity 37, 501-510 (2012
49. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 243, 147-154 (2000
50. Mellor A.L., et al. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. 175, 5601-5605 (2005
51. Floess S., et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5, e38 (2007